Literature DB >> 2443992

Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats.

J G Hay1, P L Haslam, A Dewar, B Addis, M Turner-Warwick, G J Laurent.   

Abstract

Pulmonary toxicity is an important adverse effect of bleomycin treatment. Very little is known of the mechanisms underlying the development of lung injury, especially after intravenous administration, or how it can be modulated. In this study acute lung injury induced by bleomycin has been examined in rats by assessment of alveolar lavage cell profiles, histological examination, and measurement of the total pulmonary extravascular albumin space. Intratracheal instillation of bleomycin 1.5 mg resulted in a severe pneumonitis with influx of inflammatory cells into the alveoli as assessed by alveolar lavage, oedema of the alveolar walls, and up to an eight fold increase in the total pulmonary extravascular albumin space, maximal at 72 hours. Intravenous bleomycin 0.15-5 mg produced no detectable injury when assessed in these ways. Exposure to hyperoxia (40-90%) after intravenous bleomycin, however, induced lung injury similar to that produced by intratracheal bleomycin. A much more severe injury followed administration of intravenous bleomycin after an exposure to hyperoxia, which itself resulted in lung injury; but lung injury was still detectable after bleomycin when the exposure to hyperoxia was insufficient to induce changes in control animals. Lung injury was not observed when the exposure to hyperoxia preceded bleomycin treatment. These results indicate the importance of oxygen in the pathways leading to acute lung injury following intravenous bleomycin. We conclude that exposure to oxygen might induce lung injury during and after bleomycin treatment, and suggest that in these circumstances oxygen therapy should be kept to a minimum.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443992      PMCID: PMC460759          DOI: 10.1136/thx.42.5.374

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  46 in total

1.  Ultrastructure of pulmonary bleomycin toxicity.

Authors:  C W Bedrossian; M A Luna; B Mackay; B Lichtiger
Journal:  Cancer       Date:  1973-07       Impact factor: 6.860

2.  A clinical review of bleomycin--a new antineoplastic agent.

Authors:  R H Blum; S K Carter; K Agre
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

3.  Formalin fixation for electron microscopy: a re-evaluation.

Authors:  F L Carson; J H Martin; J A Lynn
Journal:  Am J Clin Pathol       Date:  1973-03       Impact factor: 2.493

4.  Bleomycin pharmacokinetics in man. I. Intravenous administration.

Authors:  D S Alberts; H S Chen; R Liu; K J Himmelstein; M Mayersohn; D Perrier; J Gross; T Moon; A Broughton; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

5.  Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Lung volumes, volume-pressure relations, carbon monoxide uptake, and arterial blood gas studied.

Authors:  G L Snider; B R Celli; R H Goldstein; J J O'Brien; E C Lucey
Journal:  Am Rev Respir Dis       Date:  1978-02

6.  New antibiotics, bleomycin A and B.

Authors:  H Umezawa; K Maeda; T Takeuchi; Y Okami
Journal:  J Antibiot (Tokyo)       Date:  1966-09       Impact factor: 2.649

7.  Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin.

Authors:  R S Thrall; J R McCormick; R M Jack; R A McReynolds; P A Ward
Journal:  Am J Pathol       Date:  1979-04       Impact factor: 4.307

8.  Bleomycin-induced injury and metaplasia of alveolar type 2 cells. Relationship of cellular responses to drug presence in the lung.

Authors:  I Y Adamson; D H Bowden
Journal:  Am J Pathol       Date:  1979-08       Impact factor: 4.307

9.  Bleomycin lung damage: the pathology and nature of the lesion.

Authors:  A W Jones
Journal:  Br J Dis Chest       Date:  1978-10

10.  Factors influencing postoperative morbidity and mortality in patients treated with bleomycin.

Authors:  P L Goldiner; G C Carlon; E Cvitkovic; O Schweizer; W S Howland
Journal:  Br Med J       Date:  1978-06-24
View more
  6 in total

1.  Collagen breakdown during acute lung injury.

Authors:  I Y Adamson; G M King; D H Bowden
Journal:  Thorax       Date:  1988-07       Impact factor: 9.139

2.  Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis.

Authors:  N K Harrison; R J McAnulty; P L Haslam; C M Black; G J Laurent
Journal:  Thorax       Date:  1990-08       Impact factor: 9.139

3.  Intraluminal fibrosis induced unilaterally by lobar instillation of CdCl2 into the rat lung.

Authors:  V V Damiano; P V Cherian; F R Frankel; J R Steeger; M Sohn; D Oppenheim; G Weinbaum
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

Review 4.  Mechanisms of bleomycin-induced lung damage.

Authors:  J Hay; S Shahzeidi; G Laurent
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

5.  Phase-directed therapy: TSG-6 targeted to early inflammation improves bleomycin-injured lungs.

Authors:  Andrea M Foskett; Nikolay Bazhanov; Xinyu Ti; April Tiblow; Thomas J Bartosh; Darwin J Prockop
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-15       Impact factor: 5.464

6.  Bleomycin-induced lung injury in the rat: effects of the platelet-activating factor (PAF) receptor antagonist BN 52021 and platelet depletion.

Authors:  T W Evans; R J McAnulty; D F Rogers; K F Chung; P J Barnes; G J Laurent
Journal:  Environ Health Perspect       Date:  1990-04       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.